article · British Journal of Clinical Pharmacology

Impact of CYP2D62A, CYP2D64 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients

Sherouk M. Okda
Ahmed Mahmoud El Amrawy
Noha A. El‐Bassiouny
Ahmad Salahuddin
Sohila M. Elonsy
Amira B. Kassem

20241 citationOpen accessDamanhour University

Abstract

There is an association between CYP3A5*3, CYP2D6*4, CYP2D6*2A variants and bisoprolol peak concentration, which may serve as a guide in the future in choosing the optimum dose of bisoprolol in ACS patients.

Research topics

Antiplatelet Therapy and Cardiovascular Diseases
Analytical Methods in Pharmaceuticals
Pharmacogenetics and Drug Metabolism

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1111/bcp.16134

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.